Skip to main content
Press Releases

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline. "We achieved a significant milestone in Cidara's corporate evolution with the submission of an NDA for rezafungin for the treatment of candidemia and…
wpengine
August 9, 2022
Press Releases

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered…
wpengine
July 27, 2022
Press Releases

Cidara Therapeutics to Host Research and Development Day

Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th at 10 AM ET SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will host a virtual research and development day on Thursday, July 7, 2022, at 10:00…
Cidara
June 27, 2022
Press Releases

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

SAN DIEGO, May 11, 2022 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. "We continue to advance our pipeline of Cloudbreak DFC product candidates," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "Notably,…
wpengine
May 11, 2022
Press Releases

Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022

SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held virtually and in Lisbon, Portugal, from April 23-26, 2022. The…
wpengine
April 14, 2022
Press Releases

Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

CD388 is a drug-Fc conjugate (DFC) from Cidara's Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent cohorts Initial safety and pharmacokinetics data from study expected in the second half of 2022 SAN DIEGO, March 31, 2022 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today…
wpengine
March 31, 2022
Press Releases

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 07, 2022 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate activities and product pipeline. "We made significant progress on several key initiatives during the fourth quarter," said Jeffrey Stein, Ph.D., president and chief executive…
wpengine
March 7, 2022
Press Releases

Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Cidara intends to initiate the Phase 1 trial in Q1 2022 Drug-Fc conjugate (DFC) CD388 leverages Cidara's Cloudbreak® platform and has the potential to offer significant advantages over current flu vaccines in a single seasonal dose SAN DIEGO, Feb. 14, 2022 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA)…
wpengine
February 14, 2022
Press Releases

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 06, 2022 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 17,000 shares of its common stock to three new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a…
wpengine
January 6, 2022
Press Releases

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety…
wpengine
December 14, 2021

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121

p: (858) 752-6170
e: info@cidara.com

ABOUT

PIPELINE

REZAFUNGIN

CLOUDBREAK®

PUBLICATIONS

NEWSROOM

INVESTORS

CAREERS

Subscribe

© 2022 Cidara Therapeutics, Inc. | Terms of Use | Privacy and Cookies Policy